Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vectorite Biomedical's Enterprise Value for the quarter that ended in Jun. 2026 was NT$379.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectorite Biomedical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$120.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectorite Biomedical EV-to-EBIT Related Terms
Vectorite Biomedical EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vectorite Biomedical's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4170 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Vectorite Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectorite Biomedical EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vectorite Biomedical's EV-to-EBIT falls into.
Vectorite Biomedical's current Enterprise Value is NT$372.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectorite Biomedical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$120.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectorite Biomedical (ROCO:4170) has a EV-to-EBIT of 3.10 as of Sep. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vectorite Biomedical and its competitors. According to the industry distribution chart, Vectorite Biomedical ranks #105 out of 368 companies in the Biotechnology industry, placing it in the top 28.5%.
Is Vectorite Biomedical's EV-to-EBIT too high?
Vectorite Biomedical's current EV-to-EBIT is 3.10. The Biotechnology industry median EV-to-EBIT is 15.55. Vectorite Biomedical's value of 3.10 is 80.1% below this industry median. Based on the distribution chart, Vectorite Biomedical ranks #105 out of 368 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vectorite Biomedical has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectorite Biomedical ranks #105 out of 368 companies for EV-to-EBIT. This puts Vectorite Biomedical in the upper half of its industry. The industry median EV-to-EBIT is 15.55. Vectorite Biomedical's value of 3.10 is 80.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.55, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vectorite Biomedical's current EV-to-EBIT of 3.10 is 80.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vectorite Biomedical and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectorite Biomedical's current EV-to-EBIT is 3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$13.92, compared to a current price of NT$12.30 — trading 11.6% below its estimated fair value. The current EV-to-EBIT is 3.10 and 80.1% below the Biotechnology industry median of 15.55. Vectorite Biomedical's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current EV-to-EBIT is 3.10 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?
Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued.
The current stock price of NT$12.30 is trading 11.6% below its estimated GF Value™ of NT$13.92.
GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.
Key valuation signals for ROCO:4170:
EV-to-EBIT: 3.10
GF Value™: NT$13.92 vs. price of NT$12.30 (11.6% below fair value)
Industry Position: 80.1% below the Biotechnology median (#105 of 368)
No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
66GF Score
Get the complete analysis for ROCO:4170
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4170 has been successfully added to your 
